British Menopause Society tools for clinicians: Progestogens and endometrial protection
| Autor: | Haitham Hamoda |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Progestogen
business.industry Daily intake Endometrial cancer medicine.medical_treatment Obstetrics and Gynecology Physiology Estrogens Luteal phase medicine.disease Endometrial hyperplasia Menopause Endometrium Increased risk Breakthrough bleeding Endometrial Hyperplasia Humans Medicine Female Progestins medicine.symptom business reproductive and urinary physiology hormones hormone substitutes and hormone antagonists |
| Zdroj: | Post Reproductive Health. 28:40-46 |
| ISSN: | 2053-3705 2053-3691 |
| DOI: | 10.1177/20533691211058030 |
| Popis: | Progestogen administration is required to oppose naturally produced or administered estrogens to provide endometrial protection. Within HRT regimens, this should be delivered for at least the same duration as that produced during the luteal phase of the monthly cycle and in the recommended doses to protect against the risk of endometrial hyperplasia and endometrial cancer. This includes progestogens administered for 12–14 days a month in sequential regimens and continuous daily intake in continuous combined HRT regimens. Shorter durations and lower doses of progestogen intake are likely to be associated with an increased risk of breakthrough bleeding, endometrial hyperplasia, and endometrial cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|